Sprott Physical Silver Trust updates at-the-market program to $2 billion

Sprott Asset Management LP has updated the at-the-market equity program for Sprott Physical Silver Trust (NYSE:PSLV), increasing the offering to up to $2 billion of trust units in the United States and Canada. The trust, which invests primarily in physical silver bullion, currently has a market capitalization of $18.06 billion and has delivered a 204.13% return over the past year. Proceeds from the program will be used to acquire physical silver bullion.

Original reporting
Investing.com Canada · Investing.com
Published Jan 21, 2026, 7:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 21, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PSLV
Bullish
high confidence
Mentioned
$PSLV · $SLV
Relevance
6/10
AlphAI data visualization · based on Investing.com Canada
Decision brief

The 30-second read

$PSLVBullishMed
01

Why it matters

The increased at-the-market program suggests confidence in silver's future demand, which may support higher prices and benefit related investments.

02

Market read

The news is highly relevant for investors in precious metals and related ETFs, with potential short- to medium-term trading opportunities.

03

What to watch

Potential market saturation or macroeconomic headwinds could offset the positive impact of the offering on silver prices.

Relevance 6/10Timing: Immediate; news published today suggests short-term trading opportunities.

Background

Sprott Physical Silver Trust is a major holder of physical silver, and its capital raising activities can influence silver supply and prices.

Company-level read

Ticker impact

$PSLVBullishHigh confidence
Context

Primary focus of the news, as it directly relates to the company's capital raise and physical silver holdings.

Expected impact

Moderate upward pressure on PSLV's share price in the short to medium term.

Evidence & confidence

The significant increase in offering capacity suggests strong confidence in silver's future demand, which could positively influence the trust's valuation.

$SLVNeutralMedium confidence
Context

Related ETF that tracks silver prices; indirectly affected by the trust's activities.

Expected impact

Minimal; indirect influence expected.

Evidence & confidence

While increased silver buying by PSLV could support silver prices, the effect on SLV depends on broader market factors and investor sentiment.

Market effects

Strengthening of precious metals sector; increased investor interest in silver assets.

Potential uplift in North American silver markets due to US and Canadian offerings.

Moderate; silver prices are influenced by global demand and macroeconomic factors.

Counterpoint

The increased offering could lead to dilution concerns, potentially pressuring PSLV's share price downward if market sentiment shifts.

Key entities

  • Sprott Physical Silver Trust

    A trust investing primarily in physical silver bullion, traded on NYSE.

  • Investing.com

    Source of the news article.

Related articles

$BBAIHigh

Cantor Fitzgerald cuts BigBear.ai stock price target on execution concerns

Cantor Fitzgerald reduced its price target on BigBear.ai (BBAI) to $3.00 from $4.00, citing execution concerns. The stock is down 65% over the past year. BigBear.ai reported Q3 revenue of $43.6M, up 31.5% YoY, but adjusted EBITDA was negative $9.1M. The company raised its fiscal 2026 revenue guidance to $150M-$165M. Analysts do not expect profitability this year, with EPS forecast at -$0.03 for FY2026.

$MRNAHigh

Why is Moderna stock rebounding today?

Moderna (MRNA) stock rose 3.1% to $214.41 after positive Phase 3 trial data for its cancer vaccine was presented, showing a 42% reduction in melanoma recurrence risk. Piper Sandler raised its price target to $230, countering a prior downgrade. Analysts remain divided, with a consensus 'Hold' rating. The stock had fallen 18% the prior week. Earnings are due November 6.

$GMABHigh

Genmab A/S: Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab (GMAB) reported positive Phase 3 trial results for petosemtamab in combination with pembrolizumab, showing a 50% reduction in death risk for PD-L1+ head and neck cancer patients. The trial met both primary endpoints, and the company plans to engage regulators and present full results. Petosemtamab is also being evaluated in other Phase 3 trials for different cancers.